The Independent Viraleze trials at London hospital are nearing completion to report in July if as expected imo the trials show significant reduction in viral load ( significant could be up to 90% or better imo) where do we go next? The CEO indicated in her statements in Fridays article that she may already know results imo read for yourself her comments. How to management market and communicate these results regarding covid viral load reduction is this the reason for new communications role? How do we feed in the other Scripps results against flu, variants and other viral diseases into the conversation, will Viraleze be too hot for Starpharma to handle? Will some big Pharma decide they want it? After all anti viral medicines so far are not impressive and some are getting pulled from the market. One thing is for sure these results will not be able to be questioned or belittled they will stand up as Independent, significant studies done at highest level, could be interesting times for our Nasal Spray ahead imo gltah
SPL Price at posting:
41.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)